In a recent clinical trial, Lolatinib showcased remarkable success in treating advanced ALK positive non-small cell lung cancer by significantly halting disease progression. Over 60% of patients on Lolatinib were alive and progression free after five years, compared to only 8% on chryzotanib. The drug excelled in controlling disease in the brain, a common site for lung cancer metastases. Despite some side effects, experts lauded the trial results as extraordinary, delivering newfound hope to advanced lung cancer patients.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode